Reduction in Share Capital, Reverse-Stock Split Approved by Epigenomics Shareholders | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics said this week that its shareholders have approved a reduction of the firm's share capital and a five-for-one reverse-stock split.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.